Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | A Japan Patent on ITE for Cancer Intervention and Eradication Issued to AhR Pharmaceuticals, IncAhR Pharmaceuticals Announces the Issuance of its Japan Patent on ITE for Cancer Intervention and Possible Eradication by the Japan Patent Office (JPO)
ITE is an endogenous ligand or natural hormone for the aryl hydrocarbon receptor. Once binding to the receptor, ITE activates and drives the hormone-receptor complex in mediating a series of important biological and pharmacological processes in the body. Evidences collected by scientists from AhR Pharmaceuticals and a global research community as well have demonstrated ITE's potentials in treating cancer, obesity, and disorders related to imbalanced actions of immune systems. "We are committed to the building of a strong intellectual property system in developing a unique treatment and possible cure for cancer patients and this is another testimony of our effective efforts in innovation and invention in the area," said Dr. Jiasheng (Jason) Song, the Chief Scientific Officer of AhR Pharmaceuticals. "We will continue the efforts in protecting our important inventions and building values for our investors," continued Dr. Song. "More importantly, by doing that, it will ultimately enable us to do tremendously good things to benefit our patients around the globe." The patent (JP 5598775 B2 (http://www.ahrpharma.com/ AhR Pharmaceuticals, Inc., with licensed ITE technologies (http://www.warf.org/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|